Cartesian Therapeutics, Inc. (RNAC) Income Statement Analysis

See more : Pinnacle Bank (PBNK) Income Statement Analysis – Financial Results

Complete financial analysis of Cartesian Therapeutics, Inc. (RNAC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cartesian Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Cartesian Therapeutics, Inc. (RNAC)

Industry: Biotechnology

Sector: Healthcare

Website: https://selectabio.com

About Cartesian Therapeutics, Inc.

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	26.00M	110.78M	85.08M	16.60M	6.68M	903.00K	207.00K	8.08M	6.01M	3.04M
Cost of Revenue	1.55M	2.04M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	24.45M	108.74M	85.08M	16.60M	6.68M	903.00K	207.00K	8.08M	6.01M	3.04M
Gross Profit Ratio	94.03%	98.16%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Research & Development	71.84M	72.38M	68.74M	54.51M	42.74M	47.69M	45.17M	29.70M	22.98M	10.49M
General & Administrative	40.58M	23.86M	20.94M	18.91M	0.00	0.00	0.00	0.00	0.00	7.95M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	40.58M	23.86M	20.94M	18.91M	14.36M	17.26M	18.08M	12.25M	7.29M	7.95M
Other Expenses	0.00	330.00K	15.00K	89.00K	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	110.87M	96.24M	89.67M	73.42M	57.11M	64.95M	63.24M	41.95M	30.27M	18.44M
Cost & Expenses	112.42M	96.24M	89.67M	73.42M	59.13M	65.93M	63.99M	42.75M	31.32M	18.44M
Interest Income	0.00	0.00	0.00	0.00	834.00K	1.05M	617.00K	234.00K	171.00K	111.00K
Interest Expense	2.83M	3.03M	2.84M	1.56M	1.52M	1.49M	1.21M	1.25M	948.00K	552.00K
Depreciation & Amortization	843.00K	2.04M	1.72M	1.73M	2.03M	975.00K	750.00K	802.00K	1.04M	864.00K
EBITDA	-235.06M	39.84M	-5.16M	-65.59M	-51.80M	-62.87M	-63.37M	-34.16M	-23.18M	-11.46M
EBITDA Ratio	-903.95%	14.58%	-3.91%	-337.40%	-755.25%	-7,092.69%	-30,451.21%	-419.00%	-403.59%	-377.11%
Operating Income	-86.42M	14.54M	-4.60M	-56.82M	-52.46M	-65.02M	-63.78M	-34.67M	-25.30M	-15.40M
Operating Income Ratio	-332.32%	13.12%	-5.40%	-342.36%	-785.61%	-7,200.66%	-30,813.53%	-428.92%	-420.96%	-506.55%
Total Other Income/Expenses	-152.29M	20.23M	-5.12M	-12.06M	-2.90M	-314.00K	-1.54M	-1.54M	130.00K	2.52M
Income Before Tax	-238.71M	34.77M	-9.72M	-68.88M	-55.35M	-65.34M	-65.32M	-36.21M	-25.17M	-12.88M
Income Before Tax Ratio	-917.97%	31.39%	-11.43%	-414.99%	-828.97%	-7,235.44%	-31,556.04%	-447.98%	-418.80%	-423.68%
Income Tax Expense	-19.00M	-609.00K	15.97M	1.65M	1.86M	1.00	0.00	0.00	0.00	0.00
Net Income	-219.71M	35.38M	-25.69M	-68.88M	-55.35M	-65.34M	-65.32M	-36.21M	-25.17M	-12.88M
Net Income Ratio	-844.91%	31.94%	-30.19%	-414.99%	-828.97%	-7,235.44%	-31,556.04%	-447.98%	-418.80%	-423.68%
EPS	-42.49	7.33	-6.74	-20.42	-36.46	-87.55	-95.94	-103.52	-40.50	-38.17
EPS Diluted	-42.49	2.98	-6.74	-20.42	-36.46	-87.55	-95.94	-103.52	-40.50	-38.17
Weighted Avg Shares Out	5.17M	4.83M	3.81M	3.37M	1.52M	746.31K	680.83K	349.80K	621.65K	428.95K
Weighted Avg Shares Out (Dil)	5.17M	4.86M	3.81M	3.37M	1.52M	746.31K	680.83K	349.80K	621.65K	428.95K

Cartesian Therapeutics Announces New Employment Inducement Grant

September 6, 2024globenewswire.com

GAITHERSBURG, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to a new...

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

September 3, 2024globenewswire.com

Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies

Cartesian Therapeutics, Inc. (RNAC) Q2 Earnings and Revenues Top Estimates

August 8, 2024zacks.com

Cartesian Therapeutics, Inc. (RNAC) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of a loss of $0.81 per share. This compares to loss of $2.10 per share a year ago.

Cartesian Therapeutics Announces New Employment Inducement Grants

August 7, 2024globenewswire.com

GAITHERSBURG, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to seven new employees. On...

Cartesian Therapeutics Announces New Employment Inducement Grants

July 8, 2024globenewswire.com

GAITHERSBURG, Md., July 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to new employees. On...